Brief: ADC Therapeutics Announces Updates On Zynlonta® Lotis Clinical Trial Programs

Adc Therapeutics

31/08/2023 24:35

Aug 30 (Reuters) - ADC Therapeutics SA  ADCT.N :
    * ADC THERAPEUTICS ANNOUNCES UPDATES ON ZYNLONTA® LOTIS
CLINICAL
TRIAL PROGRAMS AT THE ELEVENTH ANNUAL MEETING OF THE SOCIETY OF
HEMATOLOGIC ONCOLOGY (SOHO 2023)
    * ADC THERAPEUTICS - UPDATED RESULTS FROM PHASE 3 LOTIS-5
TRIAL
DEMONSTRATE 80% ORR, 50% CR RATE AND MEDIAN DOR OF 8 MONTHS; NO
NEW SAFETY SIGNALS

Source text for Eikon:  ID:nGNE4WnjRg 
Further company coverage:  ADCT.N 

 ((Reuters.Briefs@thomsonreuters.com;))